Fetal exposure to isotretinoin in Saudi Arabia: a multicenter real-world data analysis from 2015 to 2020

Author:

Albogami Yasser1ORCID,Almadani Ohoud2,Almohareb Sumaya N.345,Alshehri Sultan6,Alkhaibari Abdullah6,Anzan Mona7,Alsharif Alaa8,Alhossan Abdulaziz6,Alrwisan Adel2

Affiliation:

1. Department of Clinical Pharmacy, College of Pharmacy, King Saud University, King Khalid Road, PO Box 145111, Riyadh 12372, Saudi Arabia

2. Saudi Food and Drug Authority, Riyadh, Saudi Arabia

3. Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

4. King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

5. Ministry of the National Guard-Health Affairs, Riyadh, Saudi Arabia

6. Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

7. Pharmacy Services, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia

8. Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia

Abstract

Background: Despite its high efficacy in treating severe acne, isotretinoin is associated with serious side effects, including teratogenicity. However, the extent of isotretinoin exposure during pregnancy in Saudi Arabia remains unknown. Objectives: This study aims to quantify the extent of fetal exposure to isotretinoin in Saudi Arabia and to evaluate adherence to risk minimization measures approved by the Saudi Food and Drug Authority. Design: Retrospective cohort study. Methods: This multicenter retrospective study included a cohort of 6233 women of childbearing ages (WCBAs) who had received isotretinoin therapy between 2015 and 2020. Exposure to isotretinoin use was ascertained from patients’ electronic health records and was defined as any positive pregnancy test (urine or serum) or any diagnosis or procedure related to pregnancy occurring during the risk period. We defined the risk period starting from isotretinoin initiation until up to 30 days after the last prescription. We quantified the overall incidence proportion of fetal exposure to isotretinoin by dividing the number of pregnancy cases during the risk period by the total study sample of WCBAs. Results: The cohort predominantly included young females (20–29 years), with a mean age of 24 years. Only 5% of the WCBAs used contraceptives, and 10% have a record of pregnancy testing. During the risk period, 34 pregnancies were identified, yielding a cumulative pregnancy incidence of 5.6 per 1000 WCBAs. Pregnancy outcomes for exposed women were about 5% of births had defects, while abortions accounted for 14.3% of pregnancies. Conclusion: Our investigation shows an alarming incidence of fetal exposure to isotretinoin in Saudi Arabia, substantially surpassing global estimates. These results underscore a critical need for enhanced interventions and robust risk minimization strategies tailored to the distinct challenges faced by the Saudi Arabian population.

Funder

Deanship of Scientific Research, King Saud University

Publisher

SAGE Publications

Reference29 articles.

1. High-Dose Isotretinoin Treatment and the Rate of Retrial, Relapse, and Adverse Effects in Patients With Acne Vulgaris

2. Retinoic Acid Embryopathy

3. U. S. Food & Drug Administration. Risk Evaluation and Mitigation Strategy (REMS): the iPLEDGE program, https://www.fda.gov/media/80023/download (2012).

4. Alisa S. Stop selling Roaccutane in private pharmacies. Alwatan Newspaper, https://www.alwatan.com.sa/a/360221 (2017, accessed 5 May 2023).

5. Epidemiology of acne vulgaris in adolescent male students in Arar, Kingdom of Saudi Arabia

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3